Exploration
Accueil
Racine
Exploration
Accueil

Corpus GrippeAllemagneV3

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Licensing and control authority batch release of influenza vaccine in Germany in accordance with EEC regulations.

Identifieur interne : 000576 ( Main/Exploration ); précédent : 000575; suivant : 000577

Licensing and control authority batch release of influenza vaccine in Germany in accordance with EEC regulations.

Auteurs : M. Weeke-Lüttmann [Allemagne]

Source :

RBID : pubmed:7843372

Descripteurs français

English descriptors

Abstract

The epidemiological situation calls for almost yearly changes in the antigenic composition of influenza vaccine, thus necessitating fresh licensing procedures. Since the time for bringing a new vaccine onto the market should be relatively short, the following work of all parties involved must be done expeditiously: 1) WHO recommendations on new virus strains and their subsequent adaptation by the EEC (February/March); 2) Distribution of the new virus strains to the International Reference Centers for Influenza in the UK and USA (February/March); the centers later issue reference materials for the determination of the haemagglutinin antigen concentration (April/May); 3) Production and testing of seed virus by manufacturers, as well as validation of the producer's inactivation process for the new virus strains (May/June); 4) Licensing of the vaccines by the National Control Authority (Paul-Ehrlich-Institute) (June/July); in the case of previously licensed products, the procedure is limited essentially to the approval of the detailed protocol of production and tests on the new virus strains, clinical studies not being required before licensing because of a lack of time; 5) Paul-Ehrlich-Institute's test for batch release, according to Directive 89/342/EEC, besides protocol approval, conducts material testing of the endotoxin and antigen content of each vaccine lot; the assay for the antigen quantification is especially laborious and sometimes must be repeated because of test invalidity.

DOI: 10.1007/BF01719692
PubMed: 7843372


Affiliations:

Links toward previous steps (curation, corpus...)

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Licensing and control authority batch release of influenza vaccine in Germany in accordance with EEC regulations.</title>
<author>
<name sortKey="Weeke Luttmann, M" sort="Weeke Luttmann, M" uniqKey="Weeke Luttmann M" first="M" last="Weeke-Lüttmann">M. Weeke-Lüttmann</name>
<affiliation wicri:level="1">
<nlm:affiliation>Paul-Ehrlich-Institut, Langen, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Paul-Ehrlich-Institut, Langen</wicri:regionArea>
<wicri:noRegion>Langen</wicri:noRegion>
<wicri:noRegion>Langen</wicri:noRegion>
<wicri:noRegion>Langen</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="1994">1994</date>
<idno type="RBID">pubmed:7843372</idno>
<idno type="pmid">7843372</idno>
<idno type="doi">10.1007/BF01719692</idno>
<idno type="wicri:Area/Main/Corpus">000592</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000592</idno>
<idno type="wicri:Area/Main/Curation">000592</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000592</idno>
<idno type="wicri:Area/Main/Exploration">000592</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Licensing and control authority batch release of influenza vaccine in Germany in accordance with EEC regulations.</title>
<author>
<name sortKey="Weeke Luttmann, M" sort="Weeke Luttmann, M" uniqKey="Weeke Luttmann M" first="M" last="Weeke-Lüttmann">M. Weeke-Lüttmann</name>
<affiliation wicri:level="1">
<nlm:affiliation>Paul-Ehrlich-Institut, Langen, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Paul-Ehrlich-Institut, Langen</wicri:regionArea>
<wicri:noRegion>Langen</wicri:noRegion>
<wicri:noRegion>Langen</wicri:noRegion>
<wicri:noRegion>Langen</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series>
<title level="j">European journal of epidemiology</title>
<idno type="ISSN">0393-2990</idno>
<imprint>
<date when="1994" type="published">1994</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Antigens, Viral (immunology)</term>
<term>Drug Approval</term>
<term>Drug Industry (legislation & jurisprudence)</term>
<term>Drug and Narcotic Control</term>
<term>Europe</term>
<term>European Union</term>
<term>Germany</term>
<term>Hemagglutinins, Viral (immunology)</term>
<term>Humans</term>
<term>Influenza Vaccines (chemical synthesis)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Influenza Vaccines (standards)</term>
<term>International Cooperation</term>
<term>Licensure</term>
<term>Orthomyxoviridae (classification)</term>
<term>Orthomyxoviridae (immunology)</term>
<term>United Kingdom</term>
<term>United States</term>
<term>Vaccines, Attenuated (chemical synthesis)</term>
<term>Vaccines, Attenuated (immunology)</term>
<term>Vaccines, Attenuated (standards)</term>
<term>World Health Organization</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Agrément de médicaments</term>
<term>Allemagne</term>
<term>Antigènes viraux (immunologie)</term>
<term>Autorisation d'exercer</term>
<term>Contrôle des médicaments et des stupéfiants</term>
<term>Coopération internationale</term>
<term>Europe</term>
<term>Humains</term>
<term>Hémagglutinines virales (immunologie)</term>
<term>Industrie pharmaceutique (législation et jurisprudence)</term>
<term>Organisation mondiale de la santé</term>
<term>Orthomyxoviridae ()</term>
<term>Orthomyxoviridae (immunologie)</term>
<term>Royaume-Uni</term>
<term>Union européenne</term>
<term>Vaccins antigrippaux (immunologie)</term>
<term>Vaccins antigrippaux (normes)</term>
<term>Vaccins antigrippaux (synthèse chimique)</term>
<term>Vaccins atténués (immunologie)</term>
<term>Vaccins atténués (normes)</term>
<term>Vaccins atténués (synthèse chimique)</term>
<term>États-Unis d'Amérique</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemical synthesis" xml:lang="en">
<term>Influenza Vaccines</term>
<term>Vaccines, Attenuated</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en">
<term>Antigens, Viral</term>
<term>Hemagglutinins, Viral</term>
<term>Influenza Vaccines</term>
<term>Vaccines, Attenuated</term>
</keywords>
<keywords scheme="MESH" qualifier="classification" xml:lang="en">
<term>Orthomyxoviridae</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr">
<term>Antigènes viraux</term>
<term>Hémagglutinines virales</term>
<term>Orthomyxoviridae</term>
<term>Vaccins antigrippaux</term>
<term>Vaccins atténués</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en">
<term>Orthomyxoviridae</term>
</keywords>
<keywords scheme="MESH" qualifier="legislation & jurisprudence" xml:lang="en">
<term>Drug Industry</term>
</keywords>
<keywords scheme="MESH" qualifier="législation et jurisprudence" xml:lang="fr">
<term>Industrie pharmaceutique</term>
</keywords>
<keywords scheme="MESH" qualifier="normes" xml:lang="fr">
<term>Vaccins antigrippaux</term>
<term>Vaccins atténués</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="standards" xml:lang="en">
<term>Influenza Vaccines</term>
<term>Vaccines, Attenuated</term>
</keywords>
<keywords scheme="MESH" qualifier="synthèse chimique" xml:lang="fr">
<term>Vaccins antigrippaux</term>
<term>Vaccins atténués</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Drug Approval</term>
<term>Drug and Narcotic Control</term>
<term>Europe</term>
<term>European Union</term>
<term>Germany</term>
<term>Humans</term>
<term>International Cooperation</term>
<term>Licensure</term>
<term>United Kingdom</term>
<term>United States</term>
<term>World Health Organization</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Agrément de médicaments</term>
<term>Allemagne</term>
<term>Autorisation d'exercer</term>
<term>Contrôle des médicaments et des stupéfiants</term>
<term>Coopération internationale</term>
<term>Europe</term>
<term>Humains</term>
<term>Organisation mondiale de la santé</term>
<term>Orthomyxoviridae</term>
<term>Royaume-Uni</term>
<term>Union européenne</term>
<term>États-Unis d'Amérique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">The epidemiological situation calls for almost yearly changes in the antigenic composition of influenza vaccine, thus necessitating fresh licensing procedures. Since the time for bringing a new vaccine onto the market should be relatively short, the following work of all parties involved must be done expeditiously: 1) WHO recommendations on new virus strains and their subsequent adaptation by the EEC (February/March); 2) Distribution of the new virus strains to the International Reference Centers for Influenza in the UK and USA (February/March); the centers later issue reference materials for the determination of the haemagglutinin antigen concentration (April/May); 3) Production and testing of seed virus by manufacturers, as well as validation of the producer's inactivation process for the new virus strains (May/June); 4) Licensing of the vaccines by the National Control Authority (Paul-Ehrlich-Institute) (June/July); in the case of previously licensed products, the procedure is limited essentially to the approval of the detailed protocol of production and tests on the new virus strains, clinical studies not being required before licensing because of a lack of time; 5) Paul-Ehrlich-Institute's test for batch release, according to Directive 89/342/EEC, besides protocol approval, conducts material testing of the endotoxin and antigen content of each vaccine lot; the assay for the antigen quantification is especially laborious and sometimes must be repeated because of test invalidity.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">7843372</PMID>
<DateCompleted>
<Year>1995</Year>
<Month>03</Month>
<Day>08</Day>
</DateCompleted>
<DateRevised>
<Year>2019</Year>
<Month>09</Month>
<Day>04</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0393-2990</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>10</Volume>
<Issue>4</Issue>
<PubDate>
<Year>1994</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>European journal of epidemiology</Title>
<ISOAbbreviation>Eur. J. Epidemiol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Licensing and control authority batch release of influenza vaccine in Germany in accordance with EEC regulations.</ArticleTitle>
<Pagination>
<MedlinePgn>513-4</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The epidemiological situation calls for almost yearly changes in the antigenic composition of influenza vaccine, thus necessitating fresh licensing procedures. Since the time for bringing a new vaccine onto the market should be relatively short, the following work of all parties involved must be done expeditiously: 1) WHO recommendations on new virus strains and their subsequent adaptation by the EEC (February/March); 2) Distribution of the new virus strains to the International Reference Centers for Influenza in the UK and USA (February/March); the centers later issue reference materials for the determination of the haemagglutinin antigen concentration (April/May); 3) Production and testing of seed virus by manufacturers, as well as validation of the producer's inactivation process for the new virus strains (May/June); 4) Licensing of the vaccines by the National Control Authority (Paul-Ehrlich-Institute) (June/July); in the case of previously licensed products, the procedure is limited essentially to the approval of the detailed protocol of production and tests on the new virus strains, clinical studies not being required before licensing because of a lack of time; 5) Paul-Ehrlich-Institute's test for batch release, according to Directive 89/342/EEC, besides protocol approval, conducts material testing of the endotoxin and antigen content of each vaccine lot; the assay for the antigen quantification is especially laborious and sometimes must be repeated because of test invalidity.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Weeke-Lüttmann</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Paul-Ehrlich-Institut, Langen, Germany.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>Eur J Epidemiol</MedlineTA>
<NlmUniqueID>8508062</NlmUniqueID>
<ISSNLinking>0393-2990</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006389">Hemagglutinins, Viral</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D017277" MajorTopicYN="N">Drug Approval</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004345" MajorTopicYN="N">Drug Industry</DescriptorName>
<QualifierName UI="Q000331" MajorTopicYN="Y">legislation & jurisprudence</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004335" MajorTopicYN="Y">Drug and Narcotic Control</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005060" MajorTopicYN="N">Europe</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005062" MajorTopicYN="Y">European Union</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005858" MajorTopicYN="N">Germany</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006389" MajorTopicYN="N">Hemagglutinins, Viral</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007252" MajorTopicYN="Y">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007391" MajorTopicYN="N">International Cooperation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008004" MajorTopicYN="Y">Licensure</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D009975" MajorTopicYN="N">Orthomyxoviridae</DescriptorName>
<QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006113" MajorTopicYN="N">United Kingdom</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName>
<QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014944" MajorTopicYN="N">World Health Organization</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="pubmed">
<Year>1994</Year>
<Month>8</Month>
<Day>1</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>1994</Year>
<Month>8</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>1994</Year>
<Month>8</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">7843372</ArticleId>
<ArticleId IdType="doi">10.1007/BF01719692</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>Allemagne</li>
</country>
</list>
<tree>
<country name="Allemagne">
<noRegion>
<name sortKey="Weeke Luttmann, M" sort="Weeke Luttmann, M" uniqKey="Weeke Luttmann M" first="M" last="Weeke-Lüttmann">M. Weeke-Lüttmann</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeAllemagneV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000576 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000576 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    GrippeAllemagneV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:7843372
   |texte=   Licensing and control authority batch release of influenza vaccine in Germany in accordance with EEC regulations.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:7843372" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a GrippeAllemagneV3
Wicri

This area was generated with Dilib version V0.6.35.
Data generation: Tue Jul 7 11:47:10 2020. Site generation: Sat Sep 26 09:55:33 2020